SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams
(mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate
(NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain.